

ABSTRACTS

- PITCHES COMPANIES -

1. Sheila Krishnadath

Novel inhibitors to inhibit the stroma-cancer cross to prevent cancer growth

Gastro-intestinal cancers such as esophageal, gastric and pancreatic cancers are still the top three gastrointestinal malignancies responsible for millions of deaths on a yearly base. Developing highly specific patient tailored targeted therapies is an unmet medical need. SMADMINX B.V. is a spin off company led by Prof. Dr. Krishnadath. SMADMINX has developed novel targeted therapies for patients with aggressive malignancies within the Gastro-intestinal which in pre-clinical studies prove to be highly effective in a specific subset of cases. The SMADMINX therapeutics are low molecular weight Llama antibodies (VHH) with high specificity against several morphogenes (BMP2 and BMP4) that act as growth factors in a subset of highly aggressive cancers. These VHHs are highly effective in inhibition of tumor growth.